Therapeutic Asset Ratings
5,108 results matching 1 filter
91,583 assets · 7,906 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Gemtuzumab Ozogamicin
Acute Myeloid Leukemia
German Cancer Research Center
P3
BB
(67)
Gemtuzumab Ozogamicin
Myelodysplastic Syndrome
National Cancer Institute (NCI)
P3
BB
(67)
Girentuximab
Nonpapillary Renal Cell Carcinoma
Massachusetts General Hospital
P3
BB
(67)
Goserelin
Male Breast Carcinoma
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
P3
BB
(67)
Hydrocortisone
Cirrhosis Of Liver
Elizabeth C. Verna
P3
BB
(67)
Hydronidone
Fibrotic Liver Disease
Beijing Continent Pharmaceutical Co, Ltd.
P3
BB
(67)
Ifosfamide
Leukemia
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
P3
BB
(67)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Colon Adenocarcinoma
IFOM ETS - The AIRC Institute of Molecular Oncology
P3
BB
(67)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Invasive Breast Carcinoma
Baylor Breast Care Center
P3
BB
(67)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Chronic Myeloid Leukemia
OHSU Knight Cancer Institute
P3
BB
(67)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
High Grade B-Cell Lymphoma
National Cancer Institute (NCI)
P3
BB
(67)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Indolent B-Cell Non-Hodgkin Lymphoma
Fox Chase Cancer Center
P3
BB
(67)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Nodal Marginal Zone B-Cell Lymphoma
City of Hope Medical Center
P3
BB
(67)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Splenic Marginal Zone Lymphoma
City of Hope Medical Center
P3
BB
(67)
Ipilimumab
Non-Small Cell Lung Carcinoma
University of Chicago
P3
BB
(67)
Irinotecan
Anal Carcinoma
University of Cincinnati
P3
BB
(67)
Irinotecan
Intestinal Neoplasm
Pfizer
P3
BB
(67)
Ixekizumab
Psoriasis
Eli Lilly and Company
P3
BB
(67)
Lacosamide
Migraine Disorder
Kafrelsheikh University
P3
BB
(67)
LENALIDOMIDE
Amyloidosis
Ascentage Pharma Group Inc.
P3
BB
(67)
Letrozole
Primary Peritoneal Serous Adenocarcinoma
NRG Oncology
P3
BB
(67)
Lomustine
Glioblastoma
Telix Pharmaceuticals (Innovations) Pty Limited
P3
BB
(67)
Lucerastat
Fabry Disease
Idorsia Pharmaceuticals Ltd.
P3
BB
(67)
MELPHALAN
Chronic Myeloid Leukemia
Center for International Blood and Marrow Transplant Research
P3
BB
(67)
MELPHALAN
Uveal Melanoma
Vastra Gotaland Region
P3
BB
(67)
Showing 876 to 900 of 5,108 assets
Previous
Page 36 of 205
Next